News >

PER Acquires, Expands Chemotherapy Foundation Symposium

Silas Inman @silasinman
Published: Thursday, May 28, 2015

Phil Talamo

Phil Talamo

The Chemotherapy Foundation Symposium, one of the largest oncology/hematology-focused conferences in the United States, was acquired last week by Physicians’ Education Resource (PER) Events, LLC, an affiliate of the accredited medical education provider PER.

The late Ezra Greenspan, MD, a pioneer and trailblazer in medical oncology, founded the Chemotherapy Foundation Symposium in 1972. The conference, which is attended by nearly 2000 healthcare professionals, will continue to be co-chaired by Edward Ambinder, MD, and Franco Muggia, MD. Prior to the acquisitions, PER’s largest event was the Miami Breast Cancer Conference, which is attended by over 1000 medical, surgical, and radiation oncologists.

For insight into how this acquisition could impact the agenda and focus of the Chemotherapy Foundation Symposium and other PER conferences, OncLive interviewed Phil Talamo, PER’s vice president of Independent Medical Education & Operations.

OncLive: What will be the focus of the 2015 Chemotherapy Foundation Symposium?

Talamo: This year’s symposium, to be held November 4 to 6 in New York City, will retain its educational focus on new developments in cancer therapeutics and state-of-the-art care. In fact, the full name itself is Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow.

This year’s meeting will continue to provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.

What are some of the anticipated hot topics at this year's meeting?

When chemotherapy was invented in the 1940s and 1950s, this was the pinnacle of innovative therapy. The first chemotherapy was actually derived from mustard gas. And it was a game-changer for patients with cancer. It is with this spirit of “innovative cancer therapy for tomorrow” that is the cornerstone of the annual Chemotherapy Foundation Symposium.

These days there are so many therapeutic options available, and many more in late-stage clinical trials. Some of them are unbelievably innovative, like immunotherapies, which actually stimulate the patients’ immune system to fight cancer. This type of “innovative cancer therapy for tomorrow” is what we will discuss at this year’s chemotherapy foundation symposium, and of course how we can best use these innovations to provide patients with state-of-the-art care.

More specifically, this year we will see expanded information on novel immuno-oncology strategies for the treatment of solid tumors and a look at the “next generation” of anti-cancer agents that address resistance mechanisms. There will be a number of sessions focused on state-of-the-art care for hematologic malignancies. The conference will provide updates on almost every type of cancer, including ovarian cancer, soft tissue sarcoma, colorectal cancer, and more.

Outside of specific cancer types, there will be sessions on predictive and prognostic markers, the potential of next-generation sequencing in the clinic, oncology informatics, EHRs [electronic health records], shared decision-making, patient access to trials, epigenetic mutations, and much more. The goal is to provide a comprehensive agenda that expands nearly all corners of ‘modern’ oncology.

What major changes or additions were made to the agenda with the acquisition?

We will retain the original format of the agenda—concise rapid-fire trial updates and interpretation that oncologists and hematologists can use in their practice immediately. This will include the treatment and management of disease across virtually every tumor type and subtype.

There will be some shifts in the agenda that reflect the “state of new data,” meaning that areas of vast data will be given more time than in previous years. This holds true to examples such as lung cancer, where we might see a historic ASCO with all the new lung data emerging. And then in multi-tumor components like immunotherapies, which will be a theme throughout the agenda as they are being studied in many different solid and liquid tumors.

What type of things do you plan to keep and continue?

We will certainly keep the spirit of the meeting and how it addresses the latest emerging developments in a comprehensive multi-tumor format. There really has never been a more exciting or more challenging time to practice oncology than there is today. We know that cancer is no longer one disease, but numerous different diseases each that can be identified with various molecular markers and other predictive and prognostic indicators. The diverse content at this year’s chemo foundation meeting will speak about the best way to personalize care for all of these different areas by using the latest information on novel and emerging therapies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication